Sun Pharmaceutical Industries’ drug manufacturing facility in Halol, Gujarat, has been issued eight observations by the U.S. Food and Drug Administration (FDA).

Generic drugmaker Natco Pharma’s active pharmaceutical igredients (API) manufacturing plant in Mekaguda, Hyderabad, has been issued a Form 483 with one observation by the U.S. Food and Drug ...

Drug major Sun Pharma on Saturday said the US health regulator has issued a Form 483 with 8 observations after inspecting its ...

Sun Pharmaceutical Industries faces scrutiny. The USFDA issued a Form 483. This follows an inspection of its Halol ...

Sun Pharma announced that the USFDA issued a Form 483 with eight observations after inspecting its Halol manufacturing plant ...

US FDA issued 8 Form 483 observations to Sun Pharma’s Halol plant following a GMP inspection in December, raise concerns.

Syngene International said that the United States Food and Drug Administration (US FDA) conducted a good clinical practices (GCP) compliance inspection of the company's facility located at Semicon ...

NATCO Pharma said that the U.S. Food and Drug Administration (FDA) had conducted an inspection at the API manufacturing plant located in Mekaguda, Hyderabad, India, which was conducted from 09 to 13 ...